Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014
Cited by 1,771 works. doi:10.1016/s0140-6736(14)60958-2
Authors
- Caroline Robert
- Antoni Ribas
- Jedd D. Wolchok
- Frank Stephen Hodi
- Omid Hamid
- Richard F. Kefford
- Jeffrey S. Weber
- Anthony Michael Joshua
- Wen‐Jen Hwu
- Tara C. Gangadhar
- Amita Patnaik
- Roxana Stefania Dronca
- Hassane M. Zarour
- Richard Wayne Joseph
- Peter D. Boasberg
- Bartosz Chmielowski
- Christine Mateus
- Michael Andrew Postow
- Kevin Gergich
- Jeroen Elassaiss‐Schaap
References
- The Statistical Analysis of Failure Time Data.
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- The blockade of immune checkpoints in cancer immunotherapy
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Nivolumab plus Ipilimumab in Advanced Melanoma